Dr. Thomas O'donnell, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 693 Main St, Amherst Commons, Suite D, Lumberton, NJ 08048 Phone: 609-261-4058 Fax: 609-261-8381 |
Dr. Karen Kaighn, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 693 Main St, Lumberton, NJ 08048 Phone: 609-261-9587 Fax: 609-261-8381 |
Dr. Richard King, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 693 Main St, Lumberton, NJ 08048 Phone: 609-261-4058 Fax: 609-261-8381 |
Dr. Melissa Doyle Labroli, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 693 Main St Bldg 3, Lumberton, NJ 08048 Phone: 609-261-4058 Fax: 609-261-8381 |
Mr. Charles Edrick Ong Chua, Pediatrics Medicare: Medicare Enrolled Practice Location: 693 Main Street, Building D Suite 1, Lumberton, NJ 08048 Phone: 609-261-4058 |
Michelle Wilke, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 693 Main St Ste D, Lumberton, NJ 08048 Phone: 609-261-4058 |
Dr. Marius Wechsler, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 693 Main St, Lumberton, NJ 08048 Phone: 609-261-4058 Fax: 609-261-8381 |
News Archive
MRSA Survivors Network, the Chicago-based nonprofit and official organization for World MRSA Day, along with fellow MRSA activists will lift the veil of secrecy surrounding MRSA. The history making inaugural kick-off event will be held at Loyola University Chicago on October 1st. The 2009 theme is "You Can Not Change What You Do Not Acknowledge."
Today, at the European Congress of Radiation 2015, COCIR participated in the EuroSafe Call for Action. A European Society of Radiology initiative, ‘EuroSafe 2 – EuroSafe imaging call for action' was the second EuroSafe session at ECR 2015.
According to research conducted at the Oregon National Primate Research Center at Oregon Health & Science University, the commonly held belief that oral contraceptives cause weight gain appears to be false. The results of the study are published online and will appear in next month's edition of the journal Human Reproduction.
Researchers from The Australian National University have identified unique molecular signals in the body that could hold the key to developing a supplement capable of administering the health benefits of exercise to patients incapable of physical activity.
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
› Verified 8 days ago